Acute Porphyria Drug Database

A03BA03 - Hyoscyamine
Propably not porphyrinogenic
PNP

Rationale
Hoyscyamine is not metabolized by, nor is it reported to have any influence on the activity of any of the cytochrome P450 enzymes. Hyoscyamine shows no pharmacokinetic or pharmacodynamic effects that could point to porphyrinogenicity.
Chemical description
Antimuscarinic tertiary amine alkaloid, levo-isomer to atropine.
Therapeutic characteristics
Hyoscyamine is an anticholinergic used in the symptomatic reliev of gastrointestinal disorders. It is administered orally, often as a depot formulation. Confounding side effect: constipation.
Metabolism and pharmakokinetics
Hyoscyamine is not metabolized by CYP enzymes.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

References

  1. Drug reference publications
  2. DrugBank. hyoscyamine. #1060
  3. McEvoy GK, editor. hyoscyamine. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (30.03.2012). #1061
  4. Sweetman SC, editor. Martindale: The complete drug reference. Hyoscyamine. Pharmaceutical Press 2009. #1063
  5. Summary of Product Characteristics
  6. Norwegian medicines agency. Summary of Product Characteristics (SPC). Egazil. #1062

Similar drugs
Explore alternative drugs in similar therapeutic classes A03B / A03BA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙